F-1: SciSparc Eyes $20 Million Capital Injection Through Share Offering

SciSparc Ltd. plans to offer up to 5,402,887 ordinary shares for resale by YA II PN, LTD., potentially raising up to $20 million through a standby equity purchase agreement.

Summary

• SciSparc Ltd. has filed a registration statement for the potential resale of up to 5,402,887 ordinary shares by YA II PN, LTD.
• This includes 55,293 commitment shares and up to 5,347,594 ordinary shares that may be sold to YA under a Standby Equity Purchase Agreement (SEPA).
• The SEPA allows SciSparc to sell up to $20 million of its ordinary shares to YA over a three-year period.
• To date, SciSparc has not sold any ordinary shares to YA under the SEPA, other than the commitment shares.
• Shares will be purchased by YA at 97% of the market price, defined as the lowest daily volume-weighted average price during the three trading days following an advance notice.
• SciSparc will not receive any proceeds from the resale of shares by YA, but may receive up to $20 million from sales to YA under the SEPA.
• The funds raised will be used for working capital and general corporate purposes.
• SciSparc has issued 55,293 ordinary shares to YA as a commitment fee of $200,000.
• The company is developing cannabinoid therapies for Tourette's syndrome, Alzheimer's disease, autism spectrum disorder, and pain.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the terms of a share offering and related agreements. While the potential capital raise is positive, the document also acknowledges risks associated with the investment and the company's financial condition, resulting in a neutral sentiment score.

Positives

• The SEPA provides SciSparc with a flexible funding mechanism over the next three years.
• SciSparc retains control over the timing and amount of share sales to YA.
• YA is prohibited from engaging in short selling or hedging transactions related to SciSparc's ordinary shares.
• The company has potential treatments for multiple conditions in its pipeline.

Negatives

• SciSparc will not receive any proceeds from the resale of shares by YA.
• The actual gross proceeds from the sale of shares may be substantially less than the $20 million total commitment under the SEPA.
• Future sales and issuances of ordinary shares might result in significant dilution and could cause the price of the ordinary shares to decline.

Risks

• Investing in SciSparc's ordinary shares involves a high degree of risk.
• The market price of SciSparc's securities may be highly volatile.
• The company may be unable to obtain additional funding when needed.
• The company is heavily dependent on the success of its pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties to conduct its preclinical and clinical studies and perform other tasks for it.
• The company may be subject to claims challenging the inventorship of its intellectual property.
• The intended restructuring plan may not be completed in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.

Future Outlook

SciSparc intends to use any proceeds received from sales of its ordinary shares to YA under the SEPA for working capital, general corporate purposes, and pursuing strategic opportunities.

Industry Context

The document highlights SciSparc's focus on cannabinoid therapies, placing it within the rapidly evolving pharmaceutical and biotechnology industries, where companies are actively developing treatments for various conditions using cannabinoids.

Comparison to Industry Standards

• The document mentions GW Pharmaceuticals (now part of Jazz Pharmaceuticals) as a key player in the cannabinoid therapeutics space, particularly with Epidiolex for epilepsy.
• Other companies mentioned include Zynerba Pharmaceuticals, Skye Bioscience, Corbus Pharmaceuticals Holdings, RespireRx Pharmaceutical Inc., Synendos Therapeutics AG, and Inversago Pharma, all of which are developing cannabinoid-based treatments for various conditions.
• The document notes that Marinol, a THC-based pharmaceutical developed by Unimed Pharmaceuticals (now marketed by AbbVie), was the first FDA-approved cannabinoid drug.
• The document highlights that the market for rare diseases, which SciSparc is targeting, typically sees high pricing for medications.

Stakeholder Impact

• Shareholders may experience dilution if SciSparc issues additional ordinary shares.
• The market price of SciSparc's ordinary shares may be affected by the offering.
• The company's ability to fund its operations and develop its product candidates may be impacted by the success of the offering.

Next Steps

• SciSparc may elect to sell ordinary shares to YA under the SEPA.
• YA may resell the ordinary shares included in the prospectus.
• SciSparc may request Pre-Paid Advances of the Commitment Amount in an amount up to $5.0 million.
• SciSparc will continue the research and development of its product candidates.
• SciSparc will seek regulatory and marketing approvals for its product candidates.

Key Dates

Keywords

SciSparc, ordinary shares, SEPA, YA II PN LTD, cannabinoid therapies, pharmaceutical, clinical stage, SPRC